國家衛生研究院 NHRI:Item 3990099045/12960
English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 852119      Online Users : 1361
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/12960


    Title: Determination of b-cell epitopes for in vitro assessment of the potency of cobra antivenoms
    Authors: Liu, BS;Wu, WG;Wu, SC;Sung, WC
    Contributors: National Institute of Infectious Diseases and Vaccinology
    Abstract: Evaluation of neutralization efficacy is a critical step for qualification of antivenom products. According to the regulation guidelines regarding the preclinical testing of cobra antivenom neutralizing potency, the only criteria for acceptance is based on the neutralization of venom lethality, which not only raises ethical concerns about using large numbers of animals, but faces a challenge in assessing the neutralizing capability on the non-lethal but medically relevant toxins. In this study, several immunoreactive epitopes of the short-chain neurotoxin and cardiotoxin A3, the two most relevant toxins identified in venom of N.atra, were identified by peptide mapping and some of the antibody recognition sites were found to be preserved among toxin variants. In addition, two epitopes detected near the proposed functional sites responsible for toxicity were found to interact with antibodies associated with neutralization against either neurotoxicity or cytotoxicity. Enzyme-linked immunosorbent assay (ELISA) was employed to determine antibody titers in commercial antivenoms against these epitopes which demonstrated high correlation with in vivo and in vitro neutralization assays. As such, a peptide-based ELISA could be developed as an in vitro complemented assay for potency evaluation at the middle process of manufacturing before moving to the preclinical assessment.
    Date: 2019-02
    Relation: Toxicon. 2019 Feb;158(Suppl. 1):S50.
    Link to: http://dx.doi.org/10.1016/j.toxicon.2018.10.174
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0041-0101&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000565208400167
    Appears in Collections:[Wang-Chou Sung] Conference Papers/Meeting Abstract

    Files in This Item:

    File Description SizeFormat
    ISI000565208400167.pdf50KbAdobe PDF222View/Open


    All items in NHRI are protected by copyright, with all rights reserved.

    Related Items in TAIR

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback